Filter by Lead Doctor (All Doctors) Revo Basho, M.D. Parvin Peddi, M.D.Janie Grumley, M.D.Erwin Grussie, M.D. Title Physician Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer, A ComboMATCH Treatment Trial NCT ID : 05554354 Protocol Number : EAY191-N2 Phase : 2 Location : Santa Monica, CA Revo Basho, M.D. Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial NCT ID : 05564377 Protocol Number : EAY191 Phase : 2 Location : Santa Monica, CA Revo Basho, M.D. Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial NCT ID : 05710328 Protocol Number : EA1211 Phase : 2 Location : Santa Monica, Ca Parvin Peddi, M.D. Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab NCT ID : 05812807 Protocol Number : A012103 Phase : 3 Location : Saint John's Cancer Institute Parvin Peddi, M.D. Known Metastatic Breast Cancer with ER-Positive and HER2-Negative Primary Lesions NCT ID : 05068726 Protocol Number : GE-280-401 Phase : 4 Location : Saint John's Cancer Institute Parvin Peddi, M.D. Biomarker Low Risk Node Positive Breast Cancer: TAILOR RT. NCT ID : 03488693 Protocol Number : CCTGMA.39 Phase : 3 Location : Santa Monica, CA Janie Grumley, M.D. Unresectable, Locally Advanced or Metastatic Triple-Negative Breast Cancer NCT ID : 04958785 Protocol Number : GS-US-586-6144 Phase : 2 Location : Saint John's Cancer Institute Parvin Peddi, M.D. Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study NCT ID : 05568472 Protocol Number : SWOG-S2010 Phase : 3 Location : Saint John's Cancer Institute Janie Grumley, M.D. A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy (Astefania) NCT ID : 04873362 Protocol Number : WO42633 Phase : 3 Location : Disney Family Cancer Center Erwin Grussie, M.D.